Scarica l'app Stockscreener
44.24
0.20%
-0.09
Pre-mercato:
43.49
-0.75
-1.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$44.33
Aprire:
$44.17
Volume 24 ore:
1.69M
Relative Volume:
0.52
Capitalizzazione di mercato:
$106.01B
Reddito:
$49.41B
Utile/perdita netta:
$5.59B
Rapporto P/E:
18.53
EPS:
2.3875
Flusso di cassa netto:
$8.32B
1 W Prestazione:
-1.29%
1M Prestazione:
+3.66%
6M Prestazione:
-4.28%
1 anno Prestazione:
-2.40%
Intervallo 1D:
$44.02
$44.36
Intervallo di 1 settimana:
$44.02
$45.23
Portata 52W:
$40.89
$52.68
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.24 | 108.19B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-16 | Downgrade | UBS | Buy → Neutral |
| 2026-01-06 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-12-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-03-21 | Iniziato | Goldman | Neutral |
| 2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Reiterato | Argus | Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Downgrade | Stifel | Buy → Hold |
| 2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Ripresa | Morgan Stanley | Overweight |
| 2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Downgrade | UBS | Buy → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Sell |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Iniziato | Bernstein | Outperform |
| 2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
| 2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
| 2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - AD HOC NEWS
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - Investing.com
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi SA (HAM:SNW2) Stock Price, Trades & News - GuruFocus
NOK Stock Slides As ADR Weakness Puts Pressure On Bulls - StocksToTrade
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
NOK Stock Slips Again As ADR Weakness Worries Traders - StocksToTrade
Sanofi stock slides as price lingers below the long-term average - Traders Union
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sahm
9 New 5-Star Stocks This Week - Morningstar
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
662283 Forecast — Price Target — Prediction for 2027 - TradingView
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims - Sahm
Sanofi faces EU probe, shares steady after Friday’s Reuters report - ad-hoc-news.de
Sanofi SA Sponsored ADR Actuals & Estimates (NASDAQ:SNY) - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY) - Seeking Alpha
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - AD HOC NEWS
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):